COLLINSVILLE, Connecticut., December 1, 2021 / PRNewswire / – Kelyniam Global, a leader in the design and manufacture of custom cranial implants, is pleased to announce that the United States Patent and Trademark Office has issued the company a notice of issued for a patent covering the company’s integrated mounting tabs, currently marketed as IFS Tabs or KwikTabs. The US patent covers the integration of fixation appendages into a cranial implant and their design. The patent was filed in 2014 and will run until 2037.

The company intends to vigorously defend the patent and will ensure that the historical and future interests of the company in this innovative technology are protected.

“The integrated fastener patent is one of the many market firsts for Kelyniam,” said Ross bjella, President and CEO. “The company was the first to use additive manufacturing to create personalized PEEK implants, the first to receive FDA certification for temporal reductions, and the first company to consistently deliver personalized implants overnight. Receipt of this patent validates Kelyniam’s commitment to innovation and our ability to bring technology to market. “

Integrated fixation can eliminate the need for expensive plates and screws, saving patients thousands of dollars per procedure. Surgeons work with a design engineer from Kelyniam to place the fixation tabs exactly where they are needed, which also facilitates surgical planning. Not having to place heavy plates and screws to fix an implant can reduce operative time, an important advantage in cranial surgery. Fewer plates and screws can also result in a more aesthetically elegant fit for the patient.

Kelyniam Inc., specializes in the rapid production of custom prosthetics using computer aided design and computer aided manufacturing of advanced medical grade polymers. The Company develops, manufactures and distributes custom cranial and maxillofacial implants for patients requiring reconstruction of cranial structures and certain facial structures. Kelyniam works directly with surgeons, healthcare systems and payers to improve clinical outcomes and the costs of care. Kelyniam’s website address is www.Kelyniam.com.

As a cautionary note to investors, certain matters discussed in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties which may cause a material difference. actual results, including the following: changes in economic conditions; general competitive factors; the Company’s ability to execute its service and product sales plans; changes in the state of the ability to market products; and the risks described from time to time in the Company’s SEC reports.

SOURCE Kelyniam Global, Inc.